SPD489 40mg
SPD489-338
Phase 3 small_molecule terminated
Quick answer
SPD489 40mg for Schizophrenia is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Schizophrenia
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated